Patents Assigned to Millennium Pharmaceuticals, Inc.
  • Patent number: 11014928
    Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: May 25, 2021
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
  • Patent number: 10953013
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: March 23, 2021
    Assignees: Millennium Pharmaceuticals, Inc., The General Hospital Corporation
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Lightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
  • Patent number: 10941211
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: March 9, 2021
    Assignees: MILLENNIUM PHARMACEUTICALS, INC., AMGEN BRITISH COLUMBIA INC.
    Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
  • Patent number: 10918716
    Abstract: The invention features new a method for treating inflammatory bowel disease, including Crohn's Disease (CD) or ulcerative colitis in a human patient, comprising administering to a patient a combination therapy comprising an anti-?4?7 antibody, a TNF? antagonist, and an immunomodulator.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: February 16, 2021
    Assignees: Millennium Pharmaceuticals, Inc., Icahn School of Medicine at Mount Sinai
    Inventors: Trevor Warren Lissoos, Jean-Frederic Colombel
  • Patent number: 10888523
    Abstract: This invention provides novel solid pharmaceutical compositions and processes for the bulk production of said compositions. This invention also provides methods of using the pharmaceutical compositions in the treatment of cancer.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: January 12, 2021
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventor: Bhavishya Mittal
  • Patent number: 10865208
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: December 15, 2020
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Sharmila Adhikari, Emily Frances Calderwood, Dylan Bradley England, Alexandra E. Gould, Sean J. Harrison, Shih-Chung Huang, Liting Ma
  • Patent number: 10786505
    Abstract: Disclosed are methods for the treatment of various solid tumors in patients in need of such treatment. The methods comprise administering to such a patient an NEDD8-activating enzyme (NAE) inhibitor such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or a pharmaceutically acceptable salt in combination with one or more chemotherapeutic agents. Also disclosed are medicaments for use in the treatment of various solid tumors.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: September 29, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Allison Berger, Eric S. Lightcap
  • Patent number: 10780090
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: September 22, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Matthew O. Duffey, Dylan England, Brian Scott Freeze, Zhigen Hu, Steven Langston, Charles McIntyre, Hirotake Mizutani, Koji Ono, He Xu
  • Patent number: 10745404
    Abstract: The present invention provides processes and synthetic intermediate (Ia) for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates. These sulfamate compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 18, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • Publication number: 20200179486
    Abstract: The invention provides methods for treating pediatric inflammatory bowel disease patients using vedolizumab.
    Type: Application
    Filed: April 26, 2018
    Publication date: June 11, 2020
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria Rosario, Michael A. Shetzline, William R. Treem
  • Patent number: 10662477
    Abstract: Disclosed herein are markers associated with sensitivity to treatment with therapeutic agents. Methods to identify markers for predicting outcome to treatment with a therapeutic agent are disclosed as well as methods to predict outcome of treatment using markers. Compositions and methods are provided to predict response to NAE inhibition or EGFR inhibition treatment.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: May 26, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen J. Blakemore, Bin Li, Hyunjin Shin, William L. Trepicchio
  • Publication number: 20200085821
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Application
    Filed: April 23, 2019
    Publication date: March 19, 2020
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Matthew O. DUFFEY, Dylan ENGLAND, Brian Scott FREEZE, Zhigen HU, Steven LANGSTON, Charles McINTYRE, Hirotake MIZUTANI, Koji ONO, He XU
  • Publication number: 20200087401
    Abstract: The invention provides methods for the treatment of chronic pouchitis comprising administering an anti-?4?7 antibody, e.g., vedolizumab, to a human subject in need thereof.
    Type: Application
    Filed: May 26, 2018
    Publication date: March 19, 2020
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria Rosario, Michael David Laurence Smyth, Hauw Tan
  • Patent number: 10538533
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: January 21, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, Tzu-Tshin Wong, He Xu, Tianlin Xu, Yingchun Ye
  • Patent number: 10533227
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: January 14, 2020
    Assignees: Millennium Pharmaceuticals, Inc., Board of Regents, University of Texas System
    Inventors: Ole Petter Veiby, Robert C. Bast, Gordon B. Mills, Gabriel N. Hortobagyi
  • Patent number: 10526351
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: January 7, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Eric L. Elliott, Abu J. Ferdous, Michael J. Kaufman, Sonja A. Komar-Lay, Debra L. Mazaik, Quentin J. Mccubbin, Phuong M. Nguyen, Vaithianathan Palaniappan, Raymond D. Skwierczynski, Nobel T. Truong, Csanad M. Varga, Peter N. Zawaneh
  • Publication number: 20200002422
    Abstract: A method for preventing GvHD in a human patient, comprising administering to a patient suffering from GvHD or at risk for GvHD, a humanized antibody having binding specificity for human ?4?7 integrin, wherein the human patient has or is going to have an allogeneic stem cell transplantation, and wherein the dosing regimen prevents, improves or eliminates GvHD.
    Type: Application
    Filed: March 13, 2017
    Publication date: January 2, 2020
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Jessica A. SACHS, John E. FORD
  • Patent number: D866757
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: November 12, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Willow Ruth Diluzio, Nobel T. Truong, Sarah Royalty Tredo, Donald Rogers, Jr.
  • Patent number: D895145
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: September 1, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Carson Smith, Richard A. Galas, Jr., Nobel Truong, Tieming Ruan, Scott Boyer
  • Patent number: D918032
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: May 4, 2021
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Carson Smith, Nobel Truong, Tieming Ruan, Scott Boyer